文献速递产科母胎医学

产后糖耐量试验结果基于标准与时机评估

Evaluation of Postpartum Glucose Tolerance Test Results Based on Criteria and Timing.
PubMed 文献 · Obstet Gynecol · 2026-03-26

该回顾性队列研究纳入妊娠期糖尿病(GDM)患者,比较传统门诊与住院/门诊混合模式下产后75g口服葡萄糖耐量试验(OGTT)完成率,并评估2022年美国糖尿病协会(ADA)标准与妇产科医师学会(ACOG)标准对糖尿病分类的影响。结果显示混合队列OGTT完成率更高(73.9% vs 31.7%,P<.001),住院测试的糖耐量异常和糖尿病诊断率高于门诊,且2022年ADA标准将多数ACOG定义的糖尿病重新分类为糖耐量异常。

要点

  • 住院筛查可提高产后OGTT完成率(73.9% vs 31.7%)。
  • 住院测试的糖耐量异常和糖尿病诊断率高于门诊测试。
  • 2022年ADA标准使多数ACOG定义的糖尿病被重新分类为糖耐量异常。

核心结论

  • 住院筛查提高产后测试率,但诊断分类因标准(ACOG vs ADA)和测试时机(产后第1天 vs 第2天)而异,需国家指南指导最佳时机和解读。

研究设计与样本

  • 单中心回顾性队列研究,纳入2023年至2025年分娩的GDM患者;传统队列(2023年1-12月)推荐门诊75g 2小时OGTT,混合队列(2024年6月-2025年6月)可选住院或门诊筛查。

主要发现

  • 传统队列6689次分娩中309例(4.6%)符合纳入标准,混合队列6312次分娩中276例(4.4%)符合。
  • 混合队列OGTT完成率高于传统队列(73.9% vs 31.7%,P<.001)。
  • 住院测试的糖耐量异常率为48.0%、糖尿病率为15.4%,高于传统门诊(19.4%和4.1%)和混合门诊(20.7%和3.4%)。
  • 应用2022年ADA标准后,多数ACOG定义的糖尿病被重新分类为糖耐量异常(Bowker χ2=24,P<.001)。
  • 调整多项回归显示,住院测试与糖耐量异常(aOR 3.06;95% CI 1.57-5.97)和显性糖尿病(aOR 4.65;95% CI 1.14-18.9)相关;产后第1天测试与糖耐量异常(aOR 2.20;95% CI 1.36-3.57)和显性糖尿病(aOR 3.92;95% CI 1.69-9.06)相关,产后第2天或之后测试无统计学显著关联。

关键数值与推荐

  • 2022年ADA标准要求糖尿病诊断需两项异常OGTT值,而非单一异常值。
  • ACOG标准与2022年ADA标准应用于OGTT结果进行回顾性分类比较。

临床怎么用

  • 考虑住院筛查以提高产后OGTT完成率,但需注意诊断标准(ACOG vs ADA)和测试时机(产后第1天 vs 第2天)对分类的影响。

局限性

  • 单中心回顾性研究,结果外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate postpartum type 2 diabetes testing and classification using the revised 2022 American Diabetes Association (ADA) diagnostic criteria, in comparison with the American College of Obstetricians & Gynecologists' (ACOG) criteria, in women with gestational diabetes mellitus (GDM) across inpatient and outpatient testing settings. Secondarily, we aimed to evaluate whether the timing of administration of the screening test was associated with differences in results. METHODS: This was a retrospective cohort study of patients with GDM who delivered at a single institution between 2023 and 2025. The traditional cohort (January-December 2023) was recommended an outpatient 75-g, 2-hour oral glucose tolerance test (OGTT). The hybrid cohort (June 2024-June 2025) was given the option of inpatient screening during the delivery hospitalization or outpatient testing. The primary outcome was OGTT completion. Secondary outcomes were diagnoses of glucose intolerance or diabetes. In January 2022, the ADA revised postpartum diagnostic criteria so that a diabetes diagnosis would require two abnormal values instead of a single abnormal OGTT value. The ACOG and 2022 ADA criteria were applied to OGTT results retrospectively to estimate their effect on postpartum diabetes classification. In a subgroup analysis, we examined whether the timing of postpartum OGTTs influenced the results. RESULTS: In the traditional cohort, 6,689 deliveries occurred; of these, 309 patients (4.6%) had GDM and met inclusion criteria. In the hybrid cohort, 6,312 deliveries occurred; of these, 276 (4.4%) patients met inclusion criteria. Rates of OGTT completion were higher in the hybrid cohort than in the traditional cohort (73.9% vs 31.7%, P <.001). Inpatient testing yielded higher rates of glucose intolerance (48.0%) and diabetes (15.4%) than outpatient testing in either cohort (traditional: 19.4% glucose intolerance and 4.1% diabetes; hybrid: 20.7% glucose intolerance and 3.4% diabetes). Application of the 2022 ADA criteria resulted in the reclassification of most ACOG-defined diabetes results as glucose intolerant (Bowker χ 2 =24, P <.001). In an adjusted multinomial regression that used ACOG criteria, inpatient testing was associated with glucose intolerance (adjusted odds ratio [aOR] 3.06; 95% CI, 1.57-5.97) and overt diabetes (aOR 4.65; 95% CI, 1.14-18.9) when compared with outpatient testing. Testing on postpartum day 1 relative to outpatient testing was associated with glucose intolerance (aOR 2.20; 95% CI, 1.36-3.57) and overt diabetes (aOR 3.92; 95% CI, 1.69-9.06), whereas testing on or after postpartum day 2 did not show a statistically significant association. CONCLUSION: Inpatient screening improves the rate of postpartum testing, but diagnostic classification varies widely by the criteria used (ACOG vs ADA) and test timing (postpartum day 1 vs 2), which underscores the need for national guidance on optimal timing and interpretation of postpartum OGTTs.

来源:Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Bastian IN, Gandhi M, Turrentine MA, et al. Evaluation of Postpartum Glucose Tolerance Test Results Based on Criteria and Timing. Obstet Gynecol. 2026. PMID: 41886750. doi:10.1097/AOG.0000000000006271

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。